Cargando…

Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia

Aim. To report our preliminary single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal sarcomatosis (PS). Methods. Eleven patients were retrospectively analyzed for perioperative details. Results. Cytoreduction com...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Zaid, Ahmed, Azzam, Ayman, Abuzaid, Mohammed, Elhassan, Tusneem, Albadawi, Naryman, Alkhatib, Lynn, AlOmar, Osama, Alsuhaibani, Abdullah, Amin, Tarek, Al-Badawi, Ismail A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860243/
https://www.ncbi.nlm.nih.gov/pubmed/27212941
http://dx.doi.org/10.1155/2016/6567473
_version_ 1782431038530650112
author Abu-Zaid, Ahmed
Azzam, Ayman
Abuzaid, Mohammed
Elhassan, Tusneem
Albadawi, Naryman
Alkhatib, Lynn
AlOmar, Osama
Alsuhaibani, Abdullah
Amin, Tarek
Al-Badawi, Ismail A.
author_facet Abu-Zaid, Ahmed
Azzam, Ayman
Abuzaid, Mohammed
Elhassan, Tusneem
Albadawi, Naryman
Alkhatib, Lynn
AlOmar, Osama
Alsuhaibani, Abdullah
Amin, Tarek
Al-Badawi, Ismail A.
author_sort Abu-Zaid, Ahmed
collection PubMed
description Aim. To report our preliminary single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal sarcomatosis (PS). Methods. Eleven patients were retrospectively analyzed for perioperative details. Results. Cytoreduction completeness (CC-0/1) was achieved in all patients with median peritoneal cancer index (PCI) of 14 ± 8.9 (range: 3–29). Combination cisplatin + doxorubicin HIPEC chemotherapy was used in 6 patients. Five patients received intraoperative radiation therapy (IORT). The median operative time, estimated blood loss, and hospital stay were 8 ± 1.4 hours (range: 6–10), 1000 ± 250 mL (range: 700–3850), and 11 ± 2.4 days (range: 7–15), respectively. Major postoperative Clavien-Dindo grade III/IV complications occurred in 1 patient and none developed HIPEC chemotherapy-related toxicities. The median overall survival (OS) and disease-free survival (DFS) after CRS + HIPEC were 28.3 ± 3.2 and 18.0 ± 4.0 months, respectively. The median follow-up time was 12 months (range: 6–33). Univariate analysis of several prognostic factors (age, gender, PS presentation/pathology, CC, PCI, HIPEC chemotherapy, and IORT) did not demonstrate statistically significant differences of OS and DFS. Conclusion. CRS + HIPEC appear to be feasible, safe, and offer survival oncological benefits. However, definitive conclusions cannot be deduced.
format Online
Article
Text
id pubmed-4860243
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48602432016-05-22 Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia Abu-Zaid, Ahmed Azzam, Ayman Abuzaid, Mohammed Elhassan, Tusneem Albadawi, Naryman Alkhatib, Lynn AlOmar, Osama Alsuhaibani, Abdullah Amin, Tarek Al-Badawi, Ismail A. Gastroenterol Res Pract Clinical Study Aim. To report our preliminary single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal sarcomatosis (PS). Methods. Eleven patients were retrospectively analyzed for perioperative details. Results. Cytoreduction completeness (CC-0/1) was achieved in all patients with median peritoneal cancer index (PCI) of 14 ± 8.9 (range: 3–29). Combination cisplatin + doxorubicin HIPEC chemotherapy was used in 6 patients. Five patients received intraoperative radiation therapy (IORT). The median operative time, estimated blood loss, and hospital stay were 8 ± 1.4 hours (range: 6–10), 1000 ± 250 mL (range: 700–3850), and 11 ± 2.4 days (range: 7–15), respectively. Major postoperative Clavien-Dindo grade III/IV complications occurred in 1 patient and none developed HIPEC chemotherapy-related toxicities. The median overall survival (OS) and disease-free survival (DFS) after CRS + HIPEC were 28.3 ± 3.2 and 18.0 ± 4.0 months, respectively. The median follow-up time was 12 months (range: 6–33). Univariate analysis of several prognostic factors (age, gender, PS presentation/pathology, CC, PCI, HIPEC chemotherapy, and IORT) did not demonstrate statistically significant differences of OS and DFS. Conclusion. CRS + HIPEC appear to be feasible, safe, and offer survival oncological benefits. However, definitive conclusions cannot be deduced. Hindawi Publishing Corporation 2016 2016-04-24 /pmc/articles/PMC4860243/ /pubmed/27212941 http://dx.doi.org/10.1155/2016/6567473 Text en Copyright © 2016 Ahmed Abu-Zaid et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Abu-Zaid, Ahmed
Azzam, Ayman
Abuzaid, Mohammed
Elhassan, Tusneem
Albadawi, Naryman
Alkhatib, Lynn
AlOmar, Osama
Alsuhaibani, Abdullah
Amin, Tarek
Al-Badawi, Ismail A.
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
title Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
title_full Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
title_fullStr Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
title_full_unstemmed Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
title_short Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
title_sort cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for management of peritoneal sarcomatosis: a preliminary single-center experience from saudi arabia
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860243/
https://www.ncbi.nlm.nih.gov/pubmed/27212941
http://dx.doi.org/10.1155/2016/6567473
work_keys_str_mv AT abuzaidahmed cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT azzamayman cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT abuzaidmohammed cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT elhassantusneem cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT albadawinaryman cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT alkhatiblynn cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT alomarosama cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT alsuhaibaniabdullah cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT amintarek cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia
AT albadawiismaila cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia